SCHEMBL20128974

SCHEMBL20128974

Cn1c2ccncc2c2ccc(-c3ccc(OCCCCCOCCCCCOCc4ccccc4)nc3)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 6/20 0.40
METAP2 P50579 1/20 0.37
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
MAOA P21397 4/20 0.36
MAOB P27338 4/20 0.36
ACHE P22303 1/20 0.36
GBA1 P04062 1/20 0.36
UGCG Q16739 1/20 0.36
GBA2 Q9HCG7 1/20 0.36
KDR P35968 1/20 0.35
LOXL2 Q9Y4K0 1/20 0.35
ELOVL1 Q9BW60 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20128962 0.89 ATM (0.36) ATMMETAP2KDR
SCHEMBL20129050 0.87 FAAH (0.39) ATMGBA1UGCGGBA2
SCHEMBL27097805 0.87 METAP2 (0.37) ATMMETAP2NPC1POLBGAA
SCHEMBL20128973 0.87 METAP2 (0.37) ATMMETAP2NPC1POLBGAA
SCHEMBL20129067 0.85 METAP2 (0.37) ATMMETAP2NPC1POLBGAA
SCHEMBL20129006 0.85 GBA1 (0.33) RXRARXRBNPC1POLBGAA
SCHEMBL20129055 0.85 FAAH (0.37) ATMGBA1UGCGGBA2
SCHEMBL20128971 0.84 ATM (0.38) ATMMETAP2
SCHEMBL27097804 0.84 ATM (0.38) ATMMETAP2
SCHEMBL20129066 0.83 METAP2 (0.38) ATMMETAP2NPC1POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN ATM 711/4885METAP2 943/4885RXRA 3536/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 ATM 959/4885METAP2 954/4885RXRA 3582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.